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Purpose. The present study investigated the potential eﬀects of long-term T3 treatment on glioma tumor cell lines. Thyroid hor-
mone action on cell growth, diﬀerentiation and survival during development may be of therapeutic relevance Methods and Results
1321N1 cell line, an astrocytoma grade II, and U87MG, a glioblastoma grade IV, were exposed for 2 and 4 days in medium de-
prived of T3 and in medium containing 1 nM T3. T3 promoted re-diﬀerentiation in both cell lines. However, T3 increased cell
proliferation in 1321N1 (2 days) which declined thereafter (4 days) while in U87MG resulted in suppression of cell proliferation. At
themolecular level, a 2.9 fold increase in the expression of TRα1 receptor was observed inU87MG versus 1321N1, P<0.05. TRβ1 re-
ceptor was undetectable. These changes corresponded to a distinct pattern of T3-induced kinase signaling activation; T3 had no
eﬀect on ERK activation in both cell lines but significantly increased phospho-Akt levels in 1321N1. Conclusion. In conclusion, T3
can re-diﬀerentiate glioma tumor cells, whereas its eﬀect on cell proliferation appears to be dependent on the type of tumor cell line
with aggressive tumors being more sensitive to T3. TRα1 receptor may, at least in part, be implicated in this response.
1. Introduction
It is now recognized that thyroid hormone (TH) may have
a critical role in the pathogenesis and the progression of the
diseases due to its regulatory action on cell diﬀerentiation,
proliferation, and survival [1]. Experimental and clinical
studies provide a growing body of evidence that TH signaling
may be altered in heart failure with important physiological
and therapeutic consequences [2]. Similarly, alterations in
TH signaling have been observed in malignancies [3, 4], and
hypothyroidism is shown to enhance tumor invasiveness and
metastasis development [5, 6]. Furthermore, in 1896, thyrox-
ine (horse thyroid extract) was the first successful hormonal
product to be used against a fulminating breast cancer [7].
Similar results were thereafter reported for a series of patients
with breast cancer in 1954 [8]. However, until now, the po-
tential of TH as cancer therapy has not been adequately ex-
plored.
Gliomas represent the most common primary brain tu-
mor and are among the most aggressive of cancers. Patients
with glioma typically relapse within a year of initial diagno-
sis [9]. Although neurosurgical resection, radiation, and
chemotherapy provide clear benefit, prognosis remains dis-
appointing. TH levels are shown to be low in patients with
gliomas but the relevance of this response to the pathophys-
iology of the disease remains largely unknown [10]. How-
ever, recent experimental studies provide evidence showing
that acute, short-term TH treatment may increase cell prolif-
eration and survival via its nongenomic action [11–13]. In
contrast, long-term TH treatment appears to suppress cell
proliferation in neuroblastoma cells [5]. Based on this evi-
dence, in the present study, we further explored the long-
term T3 eﬀects on glioma tumors in relation to the degree of
tumor aggressiveness and potential alterations in thyroid
hormone nuclear receptor (TR) expression whichmay chara-
cterize diﬀerent types of glioma cell lines. This issue although
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of clinical and therapeutic relevance has not been previously
addressed.
2. Materials and Methods
2.1. Cell Culture. 1321N1 cell line, an astrocytoma grade II,
andU87MG, a glioblastoma grade IV, were used in this study.
Glioma cell line U87MG was obtained from the American
Type Culture Collection (ATCC) (Manassas, VA), and glioma
cell line 1321N1 was obtained from the European Collection
of Cell Culture (ECACC) (Salisbury, Wiltshire, UK). All cell
lines were maintained in 150 cm2 cell culture flasks (CORN-
ING). U87MGwasmaintained in Eagle’s Essential Minimum
Medium (MEM) with Earle’s salts supplemented with 10%
fetal bovine serum (GIBCO), 1mM sodium pyruvate, strep-
tomycin and penicillin (5% v/v), 0.1mM nonessential amino
acids, 2mM L-glutamine, and amphotericin B (5% v/v).
1321N1 was maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) with glucose and sodium bicarbonate
supplemented with 10% FBS, 2mM L-glutamine, 5% peni-
cillin and streptomycin, and 5% amphotericin B.
All cell lines were maintained in a 37◦C humidified incu-
bator with 5% CO2. For all experiments, each of the glioma
cell lines was used between passages 20–30. Once cells were
70–80% confluent, they were trypsinized using 1X Trypsin.
Cells were settled for 24 h in stripped medium (using char-
coal FBS, GIBCO) before the initiation of treatment. Cells
were cultured for 48 h and 96 h either in stripped medium
only (nontreated) or in stripped medium in which 1 nM of
T3 was added.
2.2. Cell Morphology. Cell morphology was used to assess
cell diﬀerentiation. Cells were fixed in, before being viewed
with an inverted light microscope fitted with phase contrast
optics. Five random fields, each containing no more than 50
cells, were examined in each well, and the total number of
cells as well as the total number of extensions that were great-
er than two cell body diameters in length were recorded. Data
were derived from approximately 100 cells in each group. Cell
morphology could not be reliably assessed at 96 h due to
more than 80% confluency in non-treated cells.
2.3. Cell Proliferation. In order to measure cell proliferation,
BrdU labeling reagent (RPN20 kit, GE Healthcare, Piscat-
away, NJ) was added to the medium. Cells were incubated
for 30min and then fixed using 4% paraformaldehyde for
15min. Primary antibody (anti-BrdU monoclonal antibody,
dilution 1 : 100) was applied for 1 h at room temperature.
Samples were washed 3 × 5min with PBS. Secondary anti-
body (peroxidase anti-mouse IgG2a) was then applied for
30min at room temperature, followed by washing 3× 5min.
Finally, BrdU-immunostained cultures were visualized using
DAB and photographs taken with a digital camera (Zeiss
Axiovert) attached to an inverted microscope fitted with
phase contrast optics. BrdU-positive nuclei were counted as a
percentage of total nuclei. Proliferation data are derived from
between 450 to 600 cells measured in each group.
2.4. Measurement of Total Cell Number. At 2 and 4 days after
treatment, cells were washed twice with PBS, and 100 μL
trypsin 0.25% were added to each plate and incubated for
37◦C until the cells were detached. A solution of 10% FBS
in PBS was added to each plate to inhibit the trypsin action.
Then, cells were harvested, and the cell number was deter-
mined after several counts of a certain volume in Neubauer
hematocytometer.
2.5. Cell Apoptosis. Apoptotic cell nuclei were assessed by
Tunnel staining using the In Situ Cell Death Detection Kit,
according to standard protocol based on manufacturer’s in-
structions (ROCHE, Cat. No. 11 684 795 910). Cell cultures
were counterstained with Hoeschst 33358 (5 μg/mL) which
stained the nuclei of all cells. Administration of doxorubicin
is known to induce apoptosis and was used as a positive con-
trol in order to certify the selected method.
2.6. Cell Injury. Cellular injury was assessed by LDH enzyme
release in cultured medium. Culture medium was collected
at the end of the experiment for the measurement of lactate
dehydrogenase (LDH) activity (IU/L) using an ELISA kit
(Quantichrom LDH Kit, DLDH-100, BioAssay Systems,
USA).Measurements were performedwith TecanGenios sys-
tem. LDH release was expressed in each group as percentage
of the non-treated group.
2.7. Protein Isolation and Measurement of Thyroid Hormone
Receptors. After washing twice with PBS, the cells were
scraped into 400 μL lysis buﬀer containing 20mM HEPES,
pH 7.9, 10mM KCl, 1mM EDTA, 10% glycerol, 0.2% NP-
40, 0.5mM DTT, 0.5mM PMSF, 5 μg/mL aprotinin, and
5 μg/mL leupeptin. A small quantity of total lysate was kept
and the remainder centrifuged at 12000 g for 1min at 4◦C.
The nuclear fraction was prepared by resuspension of the
pellet in buﬀer containing 20mM HEPES, pH 7.9, 0.42M
NaCl, 0.2mM EDTA, 1.5mM MgCl2, 25% glycerol, 0.5mM
DTT, 0.5mM PMSF, 5 μg/mL aprotinin, and 5 μg/mL leu-
peptin and incubated with agitation for 1 hour at 4◦C
before centrifugation for 10min at 12,000 g. The resulting
supernatants were collected and used for protein analysis of
the nuclear fraction. Protein concentrations were determined
by the BCA assay method. After boiling for 5min (with 4%
SDS, 2% mercaptoethanol, and 0.004% bromophenol blue),
a quantity of 15 μg protein from nuclear or total fraction
was separated on 7.5% SDS-PAGE using a Bio-Rad Mini-
Protean gel apparatus. For Western blotting, proteins were
transferred electrophoretically to a nitrocellulose membrane
(Hybond ECL) at 100V and 4◦C, for 1.5 h using Towbin
buﬀer. After Western blotting, filters were probed with
specific antibodies against TRα1 (Abcam Rabbit polyclonal
to TRα1, ab53729, dilution 1 : 1000, o/n at 4◦C) and TRβ1
(Aﬃnity Bioreagents, MA1-216, dilution 1 : 1000, o/n at
4◦C). Filters were incubated with appropriate anti-mouse
(Amersham) or anti-rabbit (Cell Signaling) HRP secondary
antibodies. Immunoreactivity was detected by enhanced
chemiluminescence using Lumiglo reagents (New England
Biolabs). Chemiluminescence was detected by the image
analysis system FluorChem HD2 (Alpha Innotech Corpo-
ration, 14743, Catalina Street, San Leandro, CA) equipped
with a CCD camera and analysis software. Five samples from
each group were loaded on the same gel. Ponceau staining
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was used in order to normalize slight variations in protein
loading.
2.8. Determination of Kinase Signaling Activation. Filters
were probed with specific antibodies. Membranes with total
protein extracts were blocked with 5% nonfat milk in TBS-
Tween for 60min and then probed with specific antibodies
against total and phospho-ERK (Cell Signalling Technology,
dilution 1 : 1000) and total and phospho-Akt (Cell Signalling
Technology, dilution 1 : 1000), overnight at 4◦C. Filters
were incubated with appropriate anti-rabbit HRP secondary
antibody (Cell Signaling, 1 : 4000, 1 h R.T.), and immunore-
activity was detected by enhanced chemiluminescence using
Lumiglo reagents (New England Biolabs). Immunoblots
were quantified using the FluorChemHD2 system (Alpha In-
notech Corporation, 14743, Catalina Street, San Leandro,
CA). Data were obtained from n = 5 samples for each group.
2.9. Statistics. Values are presented as mean (S.E.M.). Data
were analyzed with single factor analysis of variance ANOVA
across groups. An unpaired independent sample t-test or
nonparametric Mann-Whitney test was performed, as ap-
propriate. A two-tailed test with a P value less than 0.05 was
considered significant.
3. Results
3.1. Cell Morphology. T3 induced cell rediﬀerentiation in
both cell lines studied as indicated by the significant increase
in the number of perisomatal filopodia like neurites. Thus,
in 1321N1 cells, the ratio of total number of projections to
total number of cells was 1.04 (0.14) for non-treated versus
1.9 (0.11) in T3 treated, P < 0.05. In U87-MG cells, the ratio
of total number of projections to total number of cells was
1.16 (0.14) for nontreated versus 1.83 (0.19) in T3 treated,
P < 0.05 (Figure 1).
3.2. Cell Proliferation. In 1321N1 cell cultures, at two days,
BrdU-immunostained cell nuclei were found to be 23.6% (3)
in non-treated versus 30.5% (3) in T3 treated, P < 0.05. At
4 days, cell proliferation was shown to be 45.2% (5) in non-
treated versus 40% (6) in T3 treated, P > 0.05 (Figure 2).
In U87MG cell cultures, at 2 days, BrdU-immunostained
cell nuclei were 48% (5) in nontreated versus 23.6% (4) in T3
treated, P < 0.05. In addition, after 4 days, cell proliferation
was shown to be 36.5% (6) in non-treated versus 16.3% (4)
in T3 treated, P < 0.05. (Figure 2).
3.3. LDH Release and Apoptosis. No change in LDH release
was observed either in 1321N1 or U87MG cell cultures
(Figure 2). Apoptosis was not detected either in 1321N1 or
U87MG cells (data not shown).
3.4. Total Cell Number. In 1321N1 cell cultures, at two days,
total cell number was found to be 207183 (2145) in non-
treated versus 232366 (2390) in T3 treated, P < 0.05. At
4 days, total cell number was 381105 (4100) in non-treated
versus 372433 (2595) in T3 treated, P > 0.05. (Figure 2).
0
0.5
1
1.5
2
2.5
3
∗
1321N1 number of projections (2 days)
1 nM T3Nontreated
(a)
0
0.5
1
1.5
2
2.5
1 nM T3
U87-MG number of projections (2 days)
∗
Nontreated
(b)
Figure 1: T3 induced cell re-diﬀerentiation as indicated by the sig-
nificant increase in the ratio of number of projections to total cell
number both in 1321N1 cells (a) and U87-MG cells (b) at 2 days.
Data were derived from approximately 100 cells in each group. ∗P <
0.05 versus non-treated.
In U87MG cell cultures, at 2 days, total cell number was
found to be 211300 (2078) in non treated versus 186166
(3122) in T3 treated, P < 0.05. In addition, after 4 days, total
cell number was 396866 (5791) in non-treated versus 331133
(11652) in T3 treated, P < 0.05 (Figure 2).
3.5. Thyroid Hormone Receptors Expression. A 2.9-fold in-
crease in the expression of TRα1 receptor was observed in
U87MG cells as compared to 1321N1, P < 0.05. TRβ1 re-
ceptor was undetectable in both cell lines (Figure 3).
3.6. Levels of Phospho-Akt and Phospho-ERK after T3 Treat-
ment. At two days, the ratio of p44 and p42 phospho-ERK to
total ERK in 1321N1 cells was increased 2.0-fold in T3-
treated cultures (P > 0.05) as compared to non-treated
cells. Furthermore, the ratio of phospho-Akt to total Akt was
found to be 1.4 higher in T3 treated cells as compared to non-
treated cells, P < 0.05. At 4 days, no diﬀerences in the ratio of
p44 and p42 phospho-ERK to total ERK and phospho-Akt to
total Akt were observed between the two groups (Figure 4).
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Figure 2: Cell proliferation index, LDH release, and total cell number in non-treated 1321N1 (a) and U87-MG (b) cells and after exposure
to 1 nM T3 medium concentration for 48 h and 96 h. Cell proliferation index was assessed as the percentage of BrdU-positive nuclei to the
total number of nuclei, while LDH release was expressed in each group as percentage of the untreated group. ∗P < 0.05 versus non treated.
In U87MG cells, no diﬀerences in the ratio of p44 and
p42 phospho-ERK to total ERK and phospho-Akt to total
Akt were observed between the two groups either at 2 or 4
days (Figure 5).
4. Discussion
It is now recognized that TH has important regulatory
actions beyond cell metabolism. TH is critical for cell dif-
ferentiation, proliferation, and survival during development,
and later in adult life may have regenerative/reparative action
under pathological conditions [14–16]. This unique eﬀect
could potentially be of therapeutic value in cancer therapy
[17]. Thus, in the present study, we explored the eﬀects
of TH treatment on cell diﬀerentiation, proliferation, and
survival using two diﬀerent glioma cell lines, the 1321N1,
an astrocytoma grade II, and U87MG, a glioblastoma grade
IV cell line. T3 was used at medium concentration of 1 nM
which is in the range of near physiological concentrations
and has been previously shown to suppress cell proliferation
in neuroblastoma cells [5]. This treatment resulted in cell
rediﬀerentiation in both cell lines studied as indicated by
the morphological changes and the marked increase in the
number of perisomatal filopodia like neurites. This finding is
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Figure 3: Thyroid hormone receptor α1 and β1 expression in 1321N1 cells versus U87-MG cells. Representative western blotting images are
shown. P.C. corresponds to positive control. ∗P < 0.05 versus 1321N1 cells.
in accordance with previous reports showing a transforming
eﬀect of T3 in neuroblastoma cells [5]. A series of genes re-
lated to neuroblastoma cell diﬀerentiation are shown to be
responsive to TH [18]. It is of note that this unique eﬀect of
TH has also been shown in other cancer cells and may be of
physiological and therapeutic relevance [19].
Our study further showed that the two cell lines respon-
ded diﬀerently to TH treatment as regards cell proliferation
with the more aggressive tumor cells to be more sensitive.
Thus, in 1321N1, T3 treatment resulted in increased cell
proliferation at two days which declined thereafter, while T3
had no eﬀect on cell injury. In contrast, in the U87MG cell
line, T3 markedly suppressed cell proliferation without in-
creasing cell injury. The potential underlying mechanisms of
this cell-type-dependent action of TH on cell proliferation
are not fully understood. Long-term TH eﬀects are mediated
via thyroid hormone receptors (TRs). TRs are transcription
factors which regulate important genes related to cell dif-
ferentiation, proliferation, and survival [17]. It is now reco-
gnized that TRs are altered in pathological conditions with
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Figure 4: Phosphorylated levels of Akt and p44, p42 ERK after exposure of 1321N1 cells for 2 days (a) and 4 days (b) in 1 nMT3 as compared
to non treated cells. Data were derived from n = 5 samples in each group. Representative Western blotting images are shown. ∗P < 0.05
versus non treated.
important physiological consequences. Thus, we have previ-
ously shown that TRs can change in the myocardium after
ischaemic stress or in cardiac cells exposed to growth stimuli
[20, 21]. Similarly, there is increasing evidence that altera-
tions in TRs are common events in cancer [4]. On the basis
of this evidence, we explored whether altered TR expression
in these two cell lines could possibly underlie the diﬀerential
T3 eﬀect on cell proliferation. Interestingly, TRα1 was found
to be overexpressed in U87MG cell line compared to 1321N1,
while TRβ1 receptor was undetectable in both cell lines. This
finding may indicate a potential implication of TRα1 recep-
tor in T3 action on glioma cell tumors. In fact, several lines
of evidence support this notion. TRα1 receptor has a uni-
que dual mode of function depending on thyroid hormone
availability. Thus, TRα1 in its unliganded state (aporeceptor)
instead of being inactive exerts repressive or inducible eﬀect
on the transcription of T3 inducible or repressive genes by
recruiting corepressor complexes with histone deacetylase
[22]. This is of important physiological relevance dur-
ing development with TRα1 to be overexpressed at early
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Figure 5: Phosphorylated levels of Akt and p44, p42 ERK after ex-
posure of U87-MG cells for 2 days (a) and 4 days (b) in 1 nM T3
as compared to non treated cells. Data were derived from n = 5
samples in each group. Representative Western blotting images are
shown. ∗P < 0.05 versus non treated, ∗∗P < 0.05 versus non treated
and 1 nM T3 treated cells.
embryonic stages when TH is low, resulting in cell prolifer-
ation and declines thereafter with the rise of TH resulting
in cell diﬀerentiation [1]. This fetal pattern of TRα1 expre-
ssion reemerges under pathological conditions and may lead
to pathological hypertrophy [20, 21] or promote cell cancer
proliferation [5]. The addition of TH prevents the develop-
ment of pathological cardiac hypertrophy [14] and suppress-
es cancer cell proliferation [5]. Taken together, these data re-
veal an important role of TRα1 in glioma cell aggressiveness
and response to TH. However, this issue merits further in-
vestigation.
Our study further explored whether this diﬀerential ex-
pression of TRα1 had an impact on the activation of growth
kinase (ERK and Akt) signaling activation induced by T3
treatment. These cascades are important regulators of cancer
growth and cancer cell survival [23–25]. Both Akt and ERK
are active in gliomas and have been associated with tumor
aggressiveness [26–29]. Interestingly, the present study show-
ed that T3 could significantly increase p-Akt levels in 1321N1
and not in U87MG cell line while having no eﬀect on ERK
activation in either cell line. This is in contrast with the acute
nongenomic eﬀect of T3 on U87MG cell line which was
shown to involve the activation of ERK cascade [12].
In conclusion, T3 can rediﬀerentiate glioma tumor cells.
However, the T3 eﬀect on cell proliferation appears to be de-
pendent on the type of tumor cell line with aggressive tumors
to be more sensitive to thyroid hormone treatment. TRα1 re-
ceptor may, at least in part, be implicated in this response.
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